Next Science and 3M Donate $300,000 of Breakthrough Wound Treatment to Jacksonville-Area Charity

JACKSONVILLE, Fla.–()–Next Science (ASX:NXS), an innovative medical technology company that is the leader in treating biofilm-based infections in humans, announced today that it has donated $300,000 worth of BlastX™ Antimicrobial Wound Gel to The Save A Leg, Save A Life Foundation in Ponte Vedra. The donation will support the foundation’s mission of reducing lower extremity amputations and improving wound healing outcomes through evidence-based methodology and community outreach.

“We are determined to reduce lower leg amputations, leveraging all relationships and resources to make this happen,” said The Save A Leg, Save A Life Foundation Executive Director Dr. Desmond Bell. “It takes a team approach to fulfill our mission and we are thankful to Next Science for this donation and for the healthcare practitioners providing superior wound treatment care to our communities’ most vulnerable populations.”

This gift is part of a $600,000 donation program with 3M Company, the exclusive distributor of BlastX™.

“Next Science is dedicated to helping patients and saving lives with our ground-breaking technology to treat chronic wounds,” said Dustin Haines, chief commercial officer for Next Science. “We are proud to partner with The Save A Leg, Save A Life Foundation and help them provide patients with the superior care they need to enjoy a better quality of life.”

The support to The Save A Leg, Save A Life Foundation is the second donation of BlastX™ that Next Science and 3M have made to organizations that are treating patients who are suffering from chronic wounds. The company on Nov. 10 donated $300,000 worth of BlastX™ Antimicrobial Wound Gel to Hampton Ridge Healthcare and Rehabilitation, one of New Jersey’s premier centers for skilled nursing and rehabilitative care that is in Toms River. Next Science also set up donation programs to help patients who were unable to receive treatment at wound care clinics that were closed because of COVID-19.

BlastX™ is a breakthrough antimicrobial wound gel that is powered by Next Science’s patented, non-toxic, biofilm-disruption Xbio™ technology. BlastX™ breaks down biofilm, destroys bacteria within the gel and defends against reinfection.

Biofilm, which is a naturally occurring substance, accounts for a significant percentage of hard-to-manage bacterial proliferations worldwide. The Centers for Disease Control and Prevention estimate that 80% of infections in humans are located in biofilm. In the U.S., these infections contribute to approximately 500,000 deaths each year and cost an estimated $94 billion to treat.

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development center based in Jacksonville, Florida. Established in 2012, the company’s primary focus is on the development and continued commercialization of its proprietary Xbio™ technology to reduce the impact of biofilm-based infections in human health. Xbio™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio™ technology. For further information visit:

About Save A Leg, Save A Life Foundation

The Save A Leg, Save A Life Foundation was founded in 2015 to address issues pertaining to the ever-increasing diabetic population at local and international levels, including non-healing wounds, peripheral arterial disease and lower extremity amputation. Education, philanthropy and patient advocacy are the principles Foundation has been built upon to achieve its mission. For further information visit:

About 3M

At 3M, we apply science in collaborative ways that improve lives daily. With $32 billion in sales, our 96,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at or on Twitter @3M or @3MNews.

Leave a Comment

Your email address will not be published. Required fields are marked *